HTG Molecular Diagnostics Announces Completion of $22.5 Million Aggregate Financing, Consisting of $19.0 Million Public Offering of Common Stock, Including the Exercise in Full of the Underwriter’s Option to Purchase Additional Shares, and $3.5 Million Concurrent Private Placement.
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. The company’s mission is to empower precision medicine.